Clinical Trials in Iceland

29 trials 11 recruiting 2 cities

Filter these 29 trials by condition, phase, sponsor and more.

Open in Search →

29 Registered trials

11 Recruiting

13 Completed trials

17 Sponsors active

5 Research sites

Phase III

Phase II

Phase IV

Phase III: 12 Phase II/III: 2 Phase II: 8 Phase IV: 7

Oversight events in trials active here:

9 serious breaches 8 temporary halts 1 urgent safety measure 1 unexpected event across 7 trials

View oversight register →

Top conditions

Cerebral amyloid angiopathy 2 Hypertrophic cardiomyopathy 2 Non-small cell lung cancer 1 Intensive care 1 Rheumatoid arthritis 1 Follicular lymphoma 1 Primary biliary cholangitis 1

Top sponsors

Novartis Pharma AG 5 Arctic Therapeutics ehf. 3 Karolinska University Hospital 3 Amgen Inc. 2 Cytokinetics Inc. 2 Landspitali 2 Prinses Maxima Centrum voor Kinderoncologie B.V. 2 Vaestra Goetalandsregionen 2 Aarhus Universitet 1 Aarhus University Hospital 1 AstraZeneca AB 1 Karolinska Institutet 1

Cities with most trials

All trials — page 2

29 total

Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non… Halted

2023-510082-10-00 Phase III Advanced non-small cell lung cancer harboring the KRAS G12C … Novartis Pharma AG
A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended

2023-505797-15-00 Phase III SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Cytokinetics Inc.
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Phase III Polymyalgia Rheumatica Novartis Pharma AG
Study to Evaluate Safety, Tolerability and Efficacy in patients with Primary Biliary Cholangitis of Saroglitazar Magnesium-III (EPICS-III). Ended

2024-518718-14-00 Phase II/III Primary Biliary Cholangitis (PBC) Zydus Therapeutics Inc.
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Phase III Adults at high risk of cardiovascular events without prior M… Amgen Inc.

Showing 25–29 of 29 trials

← All countries